SAB Biotherapeutics (SABS) said Tuesday additional data from a phase 1 trial of SAB-142 in patients with type 1 diabetes showed early signals of C-peptide preservation.

"While exploratory and early, the initial C-peptide data are encouraging and exactly the type of signal I hope to see at this stage," said Michael Haller, professor and chief of pediatric endocrinology, University of Florida.

"These clinical observations were supported by biomarker evidence of T cell exhaustion consistent with prior studies, strengthening confidence that the therapy is engaging its intended biological mechanism," Haller added.

The study had met its primary objectives, allowing SAB to advance SAB-142 into a phase 2b trial, which is enrolling participants, with topline data expected in H2 2027, it said.

Shares were up past 6% in afternoon trading.

Price: 4.09, Change: +0.25, Percent Change: +6.51